Sun Pharma's LEQSELVI® Shows Sustained Efficacy in Alopecia Areata

Sun Pharmaceutical Industries Limited announced that its drug LEQSELVI® (deuruxolitinib) demonstrated sustained efficacy and safety over two years in severe alopecia areata (AA) patients. Data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 showed a consistent safety profile with generally mild to moderate adverse events, and no deaths, thrombosis, or major cardiovascular events reported at the FDA-approved dose. Long-term efficacy analyses indicated durable scalp hair regrowth, with a high percentage of patients maintaining response. These findings reinforce LEQSELVI®'s potential as a long-term treatment option for severe AA.